In this study, we report the safety of coronavirus disease 2019 (COVID-19) vaccine in patients with myasthenia gravis (MG). Patients who were vaccinated against COVID-19 were included. Demographics, clinical characteristics, medications, and vaccination information were collected. The main observation outcome is the worsening of MG symptoms within 4 weeks following COVID-19 vaccination. A total of 22 patients with MG vaccinated for COVID-19 were included. Ten (45.5%) patients had ocular MG (OMG), and 12 (55.5%) patients had generalized MG (GMG). Six (27.3%) patients were female, and the mean (SD) onset age was 45.4 (11.8) years. Nineteen (86.4%) patients were seropositive for acetylcholine receptors (AChR) antibody. Seven (31.8%) patients underwent thymectomy, and four of them confirmed thymoma pathologically. Twenty-one patients were administrated with inactivated vaccines, and the remaining one was administrated with recombinant subunit vaccine. Twenty (90.9%) patients did not present MG symptom worsening within 4 weeks of COVID-19 vaccination, and two (9.1%) patients reported slight symptom worsening but resolved quickly within a few days. Our findings suggest inactivated COVID-19 vaccines might be safe in MG patients with Myasthenia Gravis Foundation of America (MGFA) classification I to II, supporting the recommendation to promote vaccination for MG patients during the still expanding COVID-19 pandemic.
【저자키워드】 COVID-19, vaccination, Safety, SARS-COV-2 infection, myasthenia gravis, 【초록키워드】 coronavirus disease, Vaccine, COVID-19 vaccine, Inactivated Vaccines, Clinical characteristics, antibody, COVID-19 pandemic, Symptom, outcome, medications, COVID-19 vaccination, female, Patient, age, receptor, information, seropositive, inactivated, Safe, Myasthenia, observation, subunit, worsening, foundation, America, ocular, collected, reported, promote, resolved, the mean, OMG, vaccinated against COVID-19, 【제목키워드】 Myasthenia, Sery,